Evidence map›Paper›PMID 41316472›Full record

ArticleJournal of experimental & clinical cancer research : CR2025

Integrative and deep learning-based prediction of therapy response in ovarian cancer.

Alicja Rajtak, Ilona Skrabalak, Natalia Ćwilichowska-Puślecka, Agnieszka Kwiatkowska-Makuch, Marcin Poręba, Natalia Skrzypczak, Alicja Krasowska, Michael Pitter, Tomasz Maj, Jan Kotarski and 1 more

Abstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alicja RajtakThe First Department of Oncologic Gynecology and Gynecology, Medical University of Lublin, Lublin, Poland.
Ilona SkrabalakThe First Department of Oncologic Gynecology and Gynecology, Medical University of Lublin, Lublin, Poland.
Natalia Ćwilichowska-PuśleckaDepartment of Chemical Biology and Bioimaging, Faculty of Chemistry, Wroclaw University of Science and Technology, Wroclaw, Poland.
Agnieszka Kwiatkowska-MakuchThe First Department of Oncologic Gynecology and Gynecology, Medical University of Lublin, Lublin, Poland.
Marcin PorębaDepartment of Chemical Biology and Bioimaging, Faculty of Chemistry, Wroclaw University of Science and Technology, Wroclaw, Poland.
Natalia SkrzypczakDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Alicja KrasowskaBiomedical Engineering, University of Michigan Medical School, Ann Arbor, MI, USA.
Michael PitterDepartment of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.
Tomasz MajSchool of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China.
Jan Kotarski *The First Department of Oncologic Gynecology and Gynecology, Medical University of Lublin, Lublin, Poland.
Karolina Okla *IOA, Lublin, Poland. kokla@med.umich.edu.

Funding

National Science Centre UMO-2020/37/B/NZ5/01984
6 · The paper itself

Abstract

Ovarian cancer comprises a highly complex ecosystem of malignant cells and their surrounding tumor microenvironment (TME), where intricate interactions shape therapeutic responses. Most current predictive models fail to capture the full extent of these interactions. Here, we performed a comprehensive multi-omic analysis of pre-treatment ovarian tumor tissues, integrating clinical, genomic, transcriptomic, and immune features to correlate with pathological therapy response. Our results show that integrating genetic and immune parameters—particularly the interplay between NK cells and TP53 status in high grade serous ovarian cancer (HGSOC), and diverse genetic alterations in non-HGSOC—markedly improves therapy response prediction. We demonstrate that tumor TP53 status governs the persistence of early NK cells in HGSOC, and this persistent NK phenotype is associated with favorable clinical outcomes. Machine learning models harnessing these multi-omic features significantly outperform those based on any single information type alone. These findings highlight the central role of the baseline tumor ecosystem and support a precision oncology framework leveraging integrated multi-omic profiling and advanced analytics to improve prediction and guide treatment strategies.

Indexed as

Deep LearningOvarian NeoplasmsFemaleHumansMultiomicsPredictive Learning ModelsPrognosisTumor MicroenvironmentCancerCyTOFHGSOCMachine learningNGSNK cellsTCF7Therapy resistanceTP53Tumor immunityTumor mutations

Identifiers

PMID41316472
PMCPMC12661774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.